SPRUCE STREET CAPITAL LP
Q2 2026 Form 13-F
NEW YORK, DELAWARE
CIK 0002050194
· CRD 333213
· SEC-registered investment adviser
$509.7M Reported Value Total
SPRUCE STREET CAPITAL LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $555,900,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $900.9M gross asset value
Hedge Fund: $900.9M
Source: Form ADV filed 2026-03-02
Reported value
$509.7M
Quarter over quarter
+19.9%
Holdings
30
Top-10 concentration
70.2%
Key People
Form ADV owners & control persons
Simon Basseyn
MANAGING MEMBER
Alex Ryan Rosen
MANAGING MEMBER
Stephen Leslie Cohen
CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 13, 2026 |
| Form | 13F-HR |
| Reported value | $509.7M |
| Positions | 30 |
| Change in reported value | +22.5% |
| New positions | 5 |
| Exited positions | 3 |
| Position turnover | 24.2% |
| Top-10 concentration | 70.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
39 | $629.0M |
|
Q2 2026 13F
Filed Aug 13, 2026
|
30 | $509.7M |
|
Q1 2026 13F
Filed May 14, 2026
|
28 | $415.9M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
27 | $302.7M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KNSA KINIKSA PHARMACEUTICALS INTL | $58.7M | 11.52% |
| 2 | RLAY RELAY THERAPEUTICS INC | $55.8M | 10.95% |
| 3 | LBRX LB PHARMACEUTICALS INC | $44.7M | 8.76% |
| 4 | RLMD RELMADA THERAPEUTICS INC | $44.2M | 8.68% |
| 5 | ANRO ALTO NEUROSCIENCE INC | $35.7M | 7.01% |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | $34.6M | 6.79% |
| 7 | ALKS ALKERMES PLC | $28.5M | 5.59% |
| 8 | SVRA SAVARA INC | $21.3M | 4.17% |
| 9 | PCVX VAXCYTE INC | $17.8M | 3.49% |
| 10 | ELVN ENLIVEN THERAPEUTICS INC | $16.7M | 3.28% |
| 11 | ENTA ENANTA PHARMACEUTICALS INC | $15.9M | 3.11% |
| 12 | CATX PERSPECTIVE THERAPEUTICS INC | $12.6M | 2.47% |
| 13 | IFRX INFLARX NV | $12.0M | 2.35% |
| 14 | SRZN SURROZEN INC | $11.2M | 2.2% |
| 15 | ALMS ALUMIS INC | $11.0M | 2.17% |
| 16 | IPSC CENTURY THERAPEUTICS INC | $9.9M | 1.95% |
| 17 | NERV MINERVA NEUROSCIENCES INC | $9.2M | 1.8% |
| 18 | SABS SAB BIOTHERAPEUTICS INC | $8.6M | 1.68% |
| 19 | ANTX AN2 THERAPEUTICS INC | $8.0M | 1.58% |
| 20 | ERAS ERASCA INC | $7.7M | 1.52% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.